Vicapsys Life Sciences, Inc. Cash And Cash Equivalents At Carrying Value

• Vicapsys Life Sciences, Inc. showed a decrease of -33.2% in Cash And Cash Equivalents At Carrying Value from 2022 to 2023.
• This data is from Vicapsys Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on October 21, 2024.
• XBRL data for this metric is available from 2019 to 2023 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2020: $30.9 thousand | Q2 2020: $5.0 thousand | Q3 2020: $1.7 thousand | Q1 2021: $30.5 thousand | Q2 2021: $170.6 thousand | Q3 2021: $165.5 thousand | Q1 2022: $101.3 thousand | Q1 2023: $4.1 thousand | Q2 2023: $231.3 thousand | Q3 2023: $53.5 thousand | Q4 2023: $9.4 thousand | Q3 2024: $89.6 thousand.
• Over the full 5 years of available data (2019 to 2023), Vicapsys Life Sciences, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 96.4%.
• Historical annual values: Fiscal year 2023: $9.4 thousand | Fiscal year 2022: $14.1 thousand | Fiscal year 2021: $217.3 thousand | Fiscal year 2020: $1.3 thousand | Fiscal year 2019: $264.2 thousand.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026